The translational regenerative medicine market has been undergoing considerable changes over the last few years. There are a number of therapies that have been launched into the market over the last few years. Stem cell therapies are being developed constantly and these are targeted at various indications, from the more common cardiovascular conditions to rarer orphan indications.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 316-pagereport you will receive 107 tables and 66 figures – all unavailable elsewhere.

7. Leading National Markets for Translational Regenerative Medicine, 2017-20277.1 The Translational Regenerative Medicine Market by Region7.1.1 The Global Distribution of Translational Regenerative Medicine in 2016 and 20177.2 Leading National Markets: Forecast 2017-20277.2.1 Changing Market Shares by Region, 2017-20277.3 Regional Translational Regenerative Medicine Markets: Analysis and Forecasts, 2017-20277.4 United States: The Largest Translational Regenerative Medicine Market7.4.1 US Translational Regenerative Medicine Market: Market Drivers and Restraints, 2017-20277.4.2 US Translational Regenerative Medicine Market: Market Forecast 2017-20277.4.3 The Regulatory Framework for Regenerative Medicine in the US7.4.4 The Impact of Ethical and Regulatory Reluctance to Embryonic Stem Cell Research and Its Impact on Funding7.4.5 How Is the Ending of Patenting for Human Gene Products Affecting the Regenerative Medicine Market in the US?7.5 Europe: A Fragmented Regenerative Medicine Market7.5.1 European Regenerative Medicine Market: Market Drivers and Restraints, 2017-20277.5.2 European Regenerative Medicine Market: Market Forecast 2017-20277.5.3 Europe’s Unitary Patent System and Its Impact on the Future of Regenerative Medicine in the Region7.5.4 Regulation of Regenerative Medicine in the European Union7.5.5 UK: A Leading Research Centre for Regenerative Medicine in Europe7.5.5.1 Regulation of Stem Cell Research in the UK7.5.6 Russia: Rising Interest in Regenerative Medicine Research7.6 Asia-Pacific: Accommodating Regulatory Landscape Aiding Rapid Product Commercialisation7.6.1 Asia-Pacific Regenerative Medicine Market: Market Drivers and Restraints, 2017-20277.6.2 Asia-Pacific Regenerative Medicine Market: Market Forecast 2017-20277.6.3 Australia: Encouraging Translational Regenerative Medicine7.6.4 China: Encouraging Stem Cell R&D7.6.4.1 Government Intervention into TRM Research in China7.6.4.2 Regulation of Stem Cell Research in China7.6.4.3 Commercialisation of Gene Therapy and Tissue Engineering Products in China7.6.4.4 Medical Tourism Impacting Market Growth for Regenerative Medicine in China7.6.5 Japan: Difficulty in Translating Research into Commercialisation7.6.5.1 Research Funding: A Major Determinant of Growth in Japan’s Regenerative Medicine7.6.5.2 Government Interventions in Promoting Stem Cell Research in Japan7.6.5.3 Regulation of Regenerative Medicine in Japan7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan7.6.6 India: An Emerging Market for Regenerative Medicine7.6.6.1 Efforts in Stem Cell Research in India7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India7.6.7 South Korea: First to Approve Stem Cell Treatments7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2017-2027

9. Qualitative Analysis for the Global Translational Regenerative Medicine Market, 2017-20279.1 Market Factors Influencing the Translational Regenerative Medicine Market9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2017-20279.3 Strengths9.3.1 Improvements in Regulatory Frameworks9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine9.3.3 Strong Support from Governments in Multiple Regions9.3.4 Increasing Ease of Product Commercialisation and Market Access9.4 Weaknesses9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth9.4.2 Lack of Funding from Venture Capital9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing9.4.4 Successful Commercialisation of TRM Products Requires New Business Models9.5 Opportunities9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets9.6 Threats9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth9.6.4 Restraints on Reimbursement May Slow Growth9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2017-20279.7.1 Threat of New Entrants9.7.2 Threat of Substitutes9.7.3 Power of Suppliers9.7.4 Power of Buyers9.7.5 Rivalry among Competitors

10. Conclusions10.1 Overview of Current Market Conditions and Market Forecast, 2017-202710.2 Leading Regenerative Medicine Segments in 2016 and 201710.3 Leading Regions in the Translational Regenerative Medicine Market in 2016 And 201710.4 Future Outlook for the Various Sectors within TRM, 2017-202710.5 R&D Pipeline Products Crucial to Future Market Growth10.6 What Does the Future Hold for Regenerative Medicine?

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com

Visiongain anticipates that the global precision medicine market is projected to witness a CAGR of 12% over the forecast period from 2020 to 2030. The global precision medicine market is anticipated to surpass US$ 67 billion in 2020 and is further projected to surpass US$ 200 billion in 2030.

The global colon targeting drug delivery market is projected to grow at a CAGR of 8.07% in the first half of the forecast period. Visiongain anticipate that the global market will witness a CAGR of 9.23% during the forecast period 2020 to 2030.